Articles

Global assays and the management of oral anticoagulation

Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the prin...

Authors: Herm Jan M Brinkman

Assays of different aspects of haemostasis – what do they measure?

Haemostasis is a complex process affected by many factors including both cellular and plasma components. It is a multistep process starting with platelet adhesion to damaged endothelium and ending in clot fibr...

Authors: Nahreen Tynngård, Tomas L Lindahl and Sofia Ramström

Superior vena cava syndrome revealing a Behçet’s disease

Behçet’s disease (BD) is a rare vasculitis in sub-Saharan Africa. Vascular thrombosis, especially venous, is common in this condition and also constitutes a basic diagnostic criterion. Its affection of the sup...

Authors: Simon Antoine Sarr, Pape Diadie Fall, Mouhamadou Chérif Mboup, Khadidiatou Dia, Malick Bodian and Modou Jobe

A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment (SRI; ...

Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Yasuyuki Abe, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana

Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects

Authors: Mikhail A Panteleev and Hendrik Coenraad Hemker

Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk

Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous conditions and states, from surgery and pregnancy to cancer, sepsis and infarction. Despite availability of antithrombotic a...

Authors: Elena N Lipets and Fazoil I Ataullakhanov

Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects

Ideal conditions for platelet reactivity testing are critical for optimal selection of a P2Y12 inhibitor. Data are inconsistent regarding the impact of high-fat meals on test assessment.

Authors: Paul P Dobesh, Jamela F Urban, Scott W Shurmur and Julie H Oestreich

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for effica...

Authors: Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, Satoru Sakagami, Hiroo Shikata, Martin H Prins, Anthonie WA Lensing, Masaharu Kato, Junichi Onuma, Yuki Miyamoto, Kazuma Iekushi and Mariko Kajikawa

A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis

Thrombosis and hemorrhage are major contributors to morbidity and mortality. The traditional laboratory tests do not supply enough information to diagnose and treat patients timely and according to their pheno...

Authors: Marcus D Lancé

Severe hyperhomocysteinemia due to cystathionine β-synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis

Homocysteine is an amino acid that is toxic to vascular endothelial cells, and plasma elevations have been associated with venous thromboembolism. Severe hyperhomocysteinemia (>100 μmol/L) may result from muta...

Authors: Zuhier Awan, Sumayah Aljenedil, David S Rosenblatt, Jean Cusson, Brian M Gilfix and Jacques Genest

Hypothermia: effects on platelet function and hemostasis

Mild therapeutic hypothermia is considered standard care in the treatment of patients resuscitated from cardiac arrest. With increasingly more frequent concomitant use of platelet-inhibiting drugs, clinicians ...

Authors: Sven Van Poucke, Kris Stevens, Abraham Emanuel Marcus and Marcus Lancé

Treatment options for venous thromboembolism: lessons learnt from clinical trials

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a common condition associated with a significant clinical and economic burden. Anticoagulant therapy is the mainstay of ...

Authors: Simon McRae

Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden

In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of thes...

Authors: Ashkan Labaf, Martin Carlwe and Peter J Svensson

Evaluation of the usefulness of a D dimer test in combination with clinical pretest probability score in the prediction and exclusion of Venous Thromboembolism by medical residents

Venous thromboembolism (VTE) requires urgent diagnosis and treatment to avoid related complications. Clinical presentations of VTE are nonspecific and require definitive confirmation by imaging techniques. A c...

Authors: Tarek Owaidah, Nahlah AlGhasham, Saad AlGhamdi, Dania AlKhafaji, Bandar ALAmro, Mohamed Zeitouni, Fawaz Skaff, Hazzaa AlZahrani, Adher AlSayed, Naser ElKum, Mahmoud Moawad, Ahmed Nasmi, Mohannad Hawari and Khalid Maghrabi

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy

Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban.

Authors: Philip S Wells, Martin Gebel, Martin H Prins, Bruce L Davidson and Anthonie WA Lensing

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment

Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of ora...

Authors: Rupert M Bauersachs, Anthonie WA Lensing, Martin H Prins, Dagmar Kubitza, Ákos F Pap, Hervé Decousus, Jan Beyer-Westendorf and Paolo Prandoni

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays

Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

Patients with deep vein thrombosis or pulmonary embolism are recommended to receive anticoagulation for acute treatment and secondary prevention of venous thromboembolism (VTE). Fast-acting direct oral anticoa...

Authors: Sebastian Harder

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants

Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as eff...

Authors: Vincent Geldhof, Christophe Vandenbriele, Peter Verhamme and Thomas Vanassche

Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study

Warfarin is known for its interaction with many drugs, resulting in undesired treatment outcomes such as bleeding. The study aimed to assess the prevalence of drug-drug interactions and determinants of bleedin...

Authors: Gebrehiwot Teklay, Nuredin Shiferaw, Befikadu Legesse and Mebratu Legesse Bekele

Successful thrombolysis following enoxaparin therapy in two pediatric patients with congenital heart disease presenting with intracardiac and cerebral thrombosis

Enoxaparin displays fibrinolytic activity through stimulation of endothelial release of tissue plasminogen activator. Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibi...

Authors: Gesa Wiegand, Vanya Icheva, Martin Schöning and Michael Hofbeck

The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI

Erythropoietin (Epo) has been shown to improve myocardial function in models of experimental myocardial infarction, but has also been associated with a rise in thromboembolic events. Thus, the aim of this stud...

Authors: Gabriele Demetz, Magdalena Laux, Armin Scherhag, Tiny Hoekstra, Marit M Suttorp, Friedo Dekker, Mark Roest, Mira Marcus-Kalish, Moshe Mittelman and Ilka Ott

Relationship between angiotensin I-converting enzyme insertion/deletion gene polymorphism and retinal vein occlusion

To evaluate the association between angiotensin I-converting enzyme insertion/deletion (ACE I/D) gene polymorphism and retinal vein occlusion (RVO). A total of 80 patients with retinal vein occlusion who was a...

Authors: Işıl Kutluturk, Ali Karagöz, Tahir Bezgin, Vecih Oduncu, Ali Elveran, Cem Doğan, Ahmet Elbay, Cevat Kirma and Yusuf Özertürk

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulati...

Authors: Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Verena Haupt, Jonas Schneider and Alexander GG Turpie

Risk of venous thromboembolic disease and adequacy of prophylaxis in hospitalized patients in Argentina: a multicentric cross-sectional study

Venous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to de...

Authors: Fernando Vazquez, Ricardo Watman, Aldo Tabares, Carina Gumpel, Enrique Baldessari, Alicia B Vilaseca, Federico J Capparelli and Esteban Lifschitz

Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression

Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent ...

Authors: Elizabeth S Mearns, C Michael White, Christine G Kohn, Jessica Hawthorne, Ju-Sung Song, Joy Meng, Jeff R Schein, Monika K Raut and Craig I Coleman

Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians

Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought ...

Authors: Stuart G Nicholls, Jamie C Brehaut, Rubab G Arim, Kelly Carroll, Richard Perez, Kaveh G Shojania, Jeremy M Grimshaw and Roy M Poses

Management of pregnancy associated venous-thromboembolism: a survey of practices

Low-molecular-weight heparin (LMWH) is frequently recommended for the treatment of pregnancy associated venous thromboembolism (PAVTE). Given that prior reports have suggested a wide variation in dosing of LMW...

Authors: Esteban Gándara, Marc Carrier and Marc A Rodger

Enhanced pre-operative thrombolytic status is associated with the incidence of deep venous thrombosis in patients undergoing total knee arthroplasty

Deep venous thrombosis (DVT), which is often associated with pulmonary embolism (PE), is a serious complication after total knee arthroplasty (TKA). In the present study, we examined the overall thrombotic and...

Authors: Yukinori Tamura, Shigeshi Mori, Shigeki Asada, Naoyuki Kawao, Shigeru Ueshima, Hiroshi Kaji, Junichiro Yamamoto, Masao Akagi and Osamu Matsuo

Thrombin based gelatin matrix and fibrin sealant mediated clot formation in the presence of clopidogrel

Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kine...

Authors: Joseph F Dwyer, Jill A McCoy, Ziping Yang, Michael Husser, Heinz Redl, Mary Ann Murphy, Martin Wolfsegger, James P DiOrio, Andreas Goppelt and Shane Donovan

The effect of a continuing medical education program on Venous thromboembolism prophylaxis utilization and mortality in a tertiary-care hospital

Venous thromboembolism (VTE) prophylaxis is underutilized for hospitalized patients. The primary objective of this study was to assess the impact of a continuing medical education (CME) program on thromboproph...

Authors: Fahad Al-Hameed, Hasan M Al-Dorzi and Essam Aboelnazer

The role of prothrombin complex concentrates in reversal of target specific anticoagulants

Over the past several years a new era for patients requiring anticoagulation has arrived. The approval of new target specific oral anticoagulants offers practitioners several advantages over traditionally used...

Authors: Katrina Babilonia and Toby Trujillo

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs

New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in so...

Authors: Raul Altman and Claudio Daniel Gonzalez

Incidence of venous thromboembolism in northern Sweden (VEINS): a population-based study

The reported incidence of venous thromboembolism (VTE) varies considerably among studies. The primary aim of this study was to describe the incidence of VTE in relation to age and sex. The secondary aim was to...

Authors: Magdalena Johansson, Lars Johansson and Marcus Lind

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire

Vitamin K Antagonists (VKAs) are widely used in clinical practice and nearly 1% of the entire population receives oral anticoagulation at least once in life. However, the rate of prescription of anticoagulatio...

Authors: Mauro Molteni and Claudio Cimminiello

TEG® and RapidTEG® are unreliable for detecting warfarin-coagulopathy: a prospective cohort study

Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, de...

Authors: C Michael Dunham, Charlene Rabel, Barbara M Hileman, Jason Schiraldi, Elisha A Chance, Mark T Shima, Alddo A Molinar and David A Hoffman

New oral anticoagulants: are coagulation units still required?

Chronic antithrombotic therapy involves the use of anticoagulants, antiplatelets given either as monotherapy or in combination for the prevention of thrombotic complications. The most feared and sometimes fata...

Authors: Raul Altman

Reviewer acknowledgement 2013

The Editors of Thrombosis Journal would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).

Authors: Yukio Ozaki and Hugo ten Cate

Paxillin is an intrinsic negative regulator of platelet activation in mice

Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signa...

Authors: Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario and Yoichi Sakata

Practical management of patients on apixaban: a consensus guide

Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mor...

Authors: Christopher Ward, Greg Conner, Geoffrey Donnan, Alexander Gallus and Simon McRae

Resolution of left atrial appendage thrombus with apixaban

Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preven...

Authors: Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka and Hiroki Ishihara

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies

The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, i...

Authors: Yuqi Wang, Chen Wang, Zhong Chen, Jiwei Zhang, Zhihong Liu, Bi Jin, Kejing Ying, Changwei Liu, Yuxia Shao, Zhicheng Jing, Isabelle Ling Meng, Martin H Prins, Ákos F Pap, Katharina Müller and Anthonie WA Lensing

Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics

Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma samples o...

Authors: Klas Boeer, Leonid Cuznetov and Wolfgang Loesche

VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets

Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induce...

Authors: Kaneo Satoh, Toshiya Hirayama, Katsuhiro Takano, Katsue Suzuki-Inoue, Tadashi Sato, Masato Ohta, Junko Nakagomi and Yukio Ozaki

Main considerable factors for correct laboratory test interpretation under DOA treatment

To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific co...

Authors: Helen Mani and Edelgard Lindhoff-Last

Isolated pancreatic heamorrhage in association with anticoagulation

Haemorrhage is the primary complication of anticoagulation therapy with the gastrointestinal, urinary and nasal tracts the most common sites of bleeding. Haematoma within solid organs is uncommon especially in...

Authors: Keith Chiu, Abdul Razack and Anthony Maraveyas

Protein-C deficiency presenting as pulmonary embolism and myocardial infarction in the same patient

Plasma protein-C exerts anticoagulatory effects by inactivating factors V and VIII. Hereditary protein C deficiency is transmitted as an autosomal dominant disorder. Homozygous individuals usually develop purp...

Authors: Syed Maqbool, Vishal Rastogi, Ashok Seth, Satbir Singh, Vijay Kumar and Arif Mustaqueem

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic ...

Authors: Martin H Prins, Anthonie WA Lensing, Rupert Bauersachs, Bonno van Bellen, Henri Bounameaux, Timothy A Brighton, Alexander T Cohen, Bruce L Davidson, Hervé Decousus, Gary E Raskob, Scott D Berkowitz and Philip S Wells

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature

Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action wh...

Authors: Faryal Tahir, Haris Riaz, Talha Riaz, Maaz B Badshah, Irbaz B Riaz, Ameer Hamza and Hafsa Mohiuddin

Activated protein C resistance in Behcet’s disease

Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most fre...

Authors: Hoda Abdel Badaee, Amr Edrees, Sherif Amin, Maher El Amir and Gaafar Ragab